Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?

Carlo Visco(University of Verona), Francesco Rodeghiero(Ospedale San Bortolo), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonino Neri(University of Milan), Silvia Finotto(Istituto Oncologico Veneto), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Marco Ruggeri(Ospedale San Bortolo), Francesco Maura(Memorial Sloan Kettering Cancer Center), Francesca Moretta(University of Verona), Achille Ambrosetti(International Extranodal Lymphoma Study Group), Erika Falisi(Ospedale San Bortolo)

Leukemia & lymphoma/Leukemia and lymphoma

September 19, 2013

10.3109/10428194.2013.834054

Cited by 17

Related Papers

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

|Blood|2008|2.6k

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

|Leukemia|2009|877

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

|Journal of Clinical Oncology|2012|682

Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)

|Blood|2012|596